STRATENYM

The UK is breaking new ground in helping patients to access innovative therapies sooner. With the refreshed Innovative Licensing and Access Pathway (ILAP), manufacturers, regulators, health technology assessment (HTA) bodies, and the UK national health system are collaborating from the earliest stages of development, providing manufacturers with coordinated guidance to accelerate access for patients with the greatest unmet needs. The first therapies to enter ILAP have been granted Innovation Passports, announced by the ILAP partners: Medicines and Healthcare products Regulatory Agency (MHRA), National Health Service (NHS), National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Therapeutics and Toxicology Centre (AWTTC). Innovation Passports provide manufacturers with early, integrated support on safety, effectiveness, and value, helping bring new therapies to patients faster. The first three investigational therapies to receive Innovation Passports fall under the following therapeutic areas: • Neonatal-onset ornithine transcarbamylase deficiency—a rare metabolic disorder that prevents the breakdown of ammonia, which can be fatal in infancy without liver transplantation. • Duchenne muscular dystrophy—a progressive, incurable muscle-wasting disease affecting 1 in 3,500–5,000 boys. • A rare, unnamed, neurodegenerative condition affecting children, with no available cure. These early efforts show how ILAP helps drive innovation in rare diseases, where development can be challenging due to limited patient numbers and evidence limitations. At STRATENYM, we’re closely tracking new developments like ILAP to help our clients navigate evolving access pathways, optimize strategies, and ensure therapies reach patients efficiently. Read more about ILAP here: https://lnkd.in/eeYHeqqD #MarketAccess #InnovationPassport #RareDisease #ILAP

This Remembrance Day, STRATENYM offices will be officially closed to honor the courage, sacrifice, and dedication of veterans, service members, and their families. We recognize the lasting impact of their service on our communities and the freedoms we are privileged to enjoy. We invite everyone to wear a poppy and pause for a moment of silence in their memory. #RemembranceDay 

🌟STRATENYM is excited to welcome Principal Consultant, Moez Ahmed, to the team! 🌟 As Principal Consultant at STRATENYM, Moez brings over five years of experience in pharmaceutical strategy, value demonstration, and advanced modelling. Previously Associate Director at a global life sciences consultancy, he has led high-impact initiatives across oncology, immunology, and rare diseases in Europe, North America, and Asia. Known for his analytical rigor and problem solving, Moez tackles complex challenges, leading to successful market access solutions from launch through late lifecycle. We are delighted to welcome Moez and anticipate the valuable expertise and contributions he will bring to our initiatives. Join us in extending a warm welcome to Moez! #Teambuilding #Marketaccess

🌍 October 26: World Amyloidosis Day Today, STRATENYM recognizes the fifth annual World Amyloidosis Day, helping to shine a light on this rare disease and the important work of the Amyloidosis Alliance: 🔹 Raising awareness about the symptoms and challenges of amyloidosis 🔹 Amplifying the voices and stories of those affected 🔹 Supporting research, care, and treatment advancements 🔹 Inspiring hope, driving change, and taking meaningful action Amyloidosis is caused by the deposition of toxic, insoluble beta-sheet fibrillar protein aggregates in various tissues. It can be either acquired or inherited and may present as a localized or systemic condition. Amyloid deposits commonly affect organs and systems such as the liver, spleen, kidneys, heart, nerves, and blood vessels, leading to a wide range of clinical manifestation. Find more details on World Amyloidosis Day here: https://lnkd.in/dG-6zZg. #RareDisease #PatientAdvocacy #HealthcareAwareness #Amyloidosis

Glasgow, we’re on our way! STRATENYM is excited to announce our participation in ISPOR Europe 2025, taking place in Glasgow, Scotland from 9–12 November. This year, STRATENYM will be represented by Christine Worsley and Daniela Goncalves Bradley, who will be presenting two insightful research projects on NICE’s Highly Specialised Technologies (HST) programme: 🔹 The Phantom Menace: How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access 🔹 A Long and Winding Road: An Evaluation of NICE HST Appraisals Taking Longer Than Two Years for Guidance Publication These studies delve into the complex pathways to patient access for rare disease treatments, and the opportunities for streamlining future appraisals. If you’ll be attending ISPOR Europe or have an interest in the evolving HEOR/HTA landscape, we’d love to connect. Let’s share insights, discuss challenges, and maybe even decode some acronyms together (we’ll keep the jargon to a minimum—promise). Reach out to connect with us in advance, we’d love to hear from you!

🦃With the Thanksgiving holiday today, we’re reflecting on the work we’ve been privileged to do and the people we’ve had the opportunity to work with this year. 🧡At STRATENYM, we're grateful to support organizations working to bring access to important treatments to patients. Helping navigate the path to access is a responsibility we don’t take lightly, and we’re proud to contribute to solutions that make a difference. Wishing you a restful and healthy Thanksgiving. #MarketAccess #PatientAccess #Thanksgiving #Gratitude

Ever been wooed by a senior partner…then found yourself in a long-term relationship with an intern? It’s called the bait-and-switch—and it’s way too common in consulting. At STRATENYM, what you see is what you get. ✨ No disappearing act. ✨ No junior swap-ins. ✨ Just seasoned experts who actually do the work. From pitch to project wrap, we’re right there with you. Because that’s how trust is built—and results delivered. #LifeSciencesConsulting #MarketAccess

HTA success comes from more than data; it’s about telling a credible, evidence-driven story. ⚠️However, submissions can be weakened by common mistakes such as: 1. Incomplete or inconsistent evidence synthesis 2. Weak alignment between clinical evidence and economic model assumptions 3. Lack of transparency in indirect. comparisons or economic modelling  4. Overlooked stakeholder (especially patient and key opinion leader) perspectives 5. Inadequate justification of model inputs or assumptions Clarity, consistency, and context are key. HTA bodies don’t just assess data, they assess how well the data supports the claimed clinical value and cost-effectiveness. 💡Avoiding these pitfalls means engaging the right expertise early, aligning strategy across functions, and maintaining continuity from evidence generation to dossier writing. 🧠At STRATENYM, we support our clients in developing HTA submissions that are both scientifically rigorous and strategically aligned, ensuring success from the very beginning. #HTA #dossier #marketaccess

Gaining market access and positive reimbursement recommendations for rare disease therapies can be challenging and complex. 🩺Rare disease treatments often face challenges such as limited clinical data, small patient populations, high per-patient costs, and an unclear patient pathway. These factors may complicate the demonstration of cost-effectiveness, the most important consideration in many HTA frameworks. At STRATENYM, we turn this challenge into a chance to showcase our strategic insights and spotlight urgent unmet needs. 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬: • Early-stage evidence planning and value communication development helps identify data gaps early and create a compelling, cross-functionally aligned narrative • Engagement with HTA bodies and payers can shape evidence plans and build rapport  • Incorporating patient-reported outcomes and lived experience strengthens value stories • Pan-European efforts like the EU JCA may help streamline access across countries We help clients balance clinical uncertainty with compelling value communication, ensuring rare therapies have the best chance to reach the patients who need them. #raredisease #marketaccess #HEOR

Market access isn’t a relay race. So why do some consultancies keep passing the baton? At STRATENYM, the same expert team supports you from strategy through to submission—no handovers, no reintroductions, no gaps in knowledge. That continuity doesn’t just make your life easier (though it definitely does); it leads to sharper insights, stronger narratives, and smoother submissions. When your consultants know your product, your data, and your story inside out, it shows: 🔸In the quality of the work 🔸In the confidence of the messaging 🔸Ultimately, in your access outcomes Continuity isn’t a luxury. It’s a competitive advantage. #MarketAccess #BoutiqueConsulting #HEOR #ContinuityMatters #AccessExcellence #PharmaConsulting